PPARG and breast carcinoma: A 2008 study found that the PPARγ ligand N-(9-fluorenyl-methyloxycarbonyl)-l-leucine (F-L-Leu) combined with the COX-2 inhibitor celecoxib significantly delayed the median age of death in breast cancer mice.